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Background: Bacterial prostatitis (BP) is a common condition accounting responsible for about 5-10% of all prostatitis
cases; chronic bacterial prostatitis (CBP) classified as type II, are less common but is a condition that significantly hampers
the quality of life, (QoL) because not only is it a physical condition but also a psychological distress. Commonly patients
are treated with antibiotics alone, and in particular fluoroquinolones are suggested by the European Urology guidelines.
This approach, although recommended, may not be enough. Thus, a multimodal approach to the prolonged antibiotic
therapy may be helpful.
Methods: 210 patients affected by chronic bacterial prostatitis were enrolled in the study. All patients were positive to
Meares-Stamey test and symptoms duration was > 3 months. The purpose of the study was to evaluate the efficacy of a
long lasting therapy with a fluoroquinolone in association with a nutraceutical supplement (prulifloxacin 600 mg for
21 days and an association of Serenoa repens 320 mg, Lactobacillus Sporogens 200 mg, Arbutin 100 mg for 30 days).
Patients were randomized in two groups (A and B) receiving respectively antibiotic alone and an association of antibiotic
plus supplement.
Results: Biological recurrence at 2 months in Group A was observed in 21 patients (27.6%) and in Group B in 6 patients
(7.8%). Uropathogens found at the first follow-up were for the majority Gram – (E. coli and Enterobacter spp.). A statistically
significant difference was found at the time of the follow-up between Group A and B in the NIH-CPSI questionnaire score,
symptoms evidence and serum PSA.
Conclusions: Broad band, short-lasting antibiotic therapy in association with a nutritional supplement (serenoa repens,
lactobacillus sporogens and arbutin) show better control and recurrence rate on patients affected by chronic bacterial
prostatitits in comparison with antibiotic treatment alone.
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Bacterial prostatitis (BP) is a common condition in
which an infective origin is accepted, and accounts for
about 5-10% of all prostatitis cases [1]. This is one of the
most common reasons for younger men to consult with a
urologist. Regarding duration of symptoms, we describe
two main types: acute and chronic. In particular, when
chronic, symptoms last more than 3 months and in
agreement with the National Institute of Health (NIH)
chronic bacterial prostatitis (CBP) is classified as type II.
Even if in many cases the aetiology is known, in others
there are only these symptoms: pelvic area pain and lower
urinary tract symptoms (LUTS). Chronic prostatitis is a
condition that significantly hampers the quality of life
(QoL) of the majority of patients affected, because it is not
only a physical condition but also a psychological distress.
The impact of CBP is similar to those patients who had a
myocardial infarction, unstable angina or Crohn’s disease
[2]. Pathophysiology of CBP at the moment remains
unknown although some mechanisms of actions, like
infectious, immunological, neurological, endocrine and
psychological, have been postulated [3]. Commonly patients
are treated with antibiotics alone as recommended by the
European Urology guidelines. In particular, for chronic
bacterial prostatitis, fluoroquinolones, thanks to their
favourable pharmacokinetic properties, prostate penetra-
tion, bioavailability and excellent activity against typical/
atypical pathogens together with a good safety profile, are
considered drugs of choice. The use of fluoroquinolones, a
broad-spectrum antibiotic, is strengthened by the
well-known evidence that CBP is commonly caused
by Gram-negative bacteria such as Escherichia coli,
and also by the recent consideration of some authors
that reported an emerging prevalence of Gram-positive
and atypical bacteria together with anaerobes [4,5].
Usually high-doses and a long-lasting therapy are preferred
because only low-molecular-weight and lipid-soluble drugs,
not tightly connected to plasma proteins, are able to pene-
trate the epithelial membrane, even considering reported
side-effects (gastrointestinal disorders and development of
antibiotics resistance) [6-8]. This approach, although
recommended, may not be enough, considering patients’
and urologists’ high rate of dissatisfaction. Furthermore,
given the overlapping of lower urinary tract symptoms,
antibiotics alone could be inadequate. The main purpose
of the therapy is to eradicate uropathogens without
forgetting to relieve symptoms that mainly act on
QoL. Considering the heterogeneous nature of chronic
prostatitis and recurrence rate of this disorder, a multi-
modal approach to the prolonged antibiotic therapy may
be helpful for the solution of the problem at hand. The
use of plant-derived products is reaching popularity
in North America and Europe and is often one of the
treatments of choice for chronic conditions [9]. Mainadvantages of such a therapy are unique mechanisms of
action, response against LUTS, low side-effects profile,
low cost and high level of acceptance by patients. Main
disadvantages are unknown drug interactions and
meaningless labels [9]. Serenoa Repens, saw palmetto
extract, is the most commonly used phyto-therapy in
urology and has an action against type I-II 5-α-reductase
(conversion of testosterone in dihydrotestosterone),
anti-inflammatory effect by inhibition of arachidonic
acid metabolites and also an anti-edematous effect
[10]. Arbutin, the active principle of bearberry, is an
antioxidant agent with an anti-inflammatory action
through lypopolisaccharide induced production of NO and
expression of iNOS and COX-2 [11]. The use of probiotics,
in particular lactobacillus sporogens, is a good alternative
for the treatment and prevention of urinary tract infection
(UTI) through different mechanisms including attachment
to the uroepithelial cells and direct antimicrobial activity
[12]. Lactobacillus is an important part of the normal flora,
which is commonly found in the mouth cavity, gastrointes-
tinal tract and genitourinary tract. Reduction in number of
lactobacillus increases the risk of UTI [13].
In the article we report results of an association therapy
with third generation fluoroquinolone (prulifloxacin
600 mg) and nutraceutical supplement (Serenoa repens
320 mg, Lactobacillus Sporogens 200 mg, Arbutin
100 mg) in the treatment of chronic bacterial prostatitis.
Methods
From January 2012 to December 2012 a total of 210
patients with an average age of 36.6 (19–54) were
enrolled in the study. In particular all of the patients
were affected by chronic bacterial prostatitis and in
accordance with the definition of the disease were
positive to the Meares-Stamey test and symptoms
duration was > 3 months (dysuria, pelvic pain and/or
discomfort). The Meares-Stamey test, also known as
4-glass test, is the standard method of assessing inflamma-
tion and presence of bacteria in the lower urinary tract of
men presenting CBP. The test has been performed on each
patient before and after the therapy. The Meares-Stamey
evaluation allows the collection of four samples: first voided
urine (VB1) that represents urethra, mid-stream urine
(VB2) that represents bladder, expressed prostatic secretion
(EPS) and post-prostatic massage urine (VB3) that repre-
sent the prostate. It is considered positive when we have
urophathogen colony-forming units (CFU)/mL ≥103.
The NIH-Chronic Prostatitis Symptom Index (NIH-CPSI)
is a questionnaire with 13 questions developed to
evaluate symptoms and quality of life in men with chronic
prostatitis/chronic pelvic pain syndrome (CP/CPPS). Every
question has a score differing by the answer, and the ques-
tionnaire has a total score ranging from 0 to 43. The score
is divided by three subscales: pain (score range 0–21),
Table 1 Patients characteristics
Group A Group B
No. of patients* 76 77
Median age (±S.D.) (years)* 35.9 (6.2) 37.1 (6.5)
Sexual bahaviour (%)
Only 1 partner* 50 (65.8) 52 (67.5)
2 or more partners* 26 (34.2) 25 (32.5)
Contraceptive method (%)
No contraceptive** 28 (36.7) 31 (40.3)
Condom* 9 (11.8) 9 (11.7)
Coitus interruptus** 39 (51.3) 37 (48.1)
Urinary symptoms (%)
Burning* 65 (85.6) 65 (84.4)
Tenesmus* 24 (31.6) 26 (33.8)
Pain** 40 (52.6) 34 (44.2)
Urgency** 40 (52.6) 32 (41.6)
Frequency** 46 (60.5) 55 (71.4)
Beginning of CBP (months)* 15.9 17.4
*not-statistically significant difference between Group A and B.
**statistically significant difference between Group A and B.
Table 2 Uropathogens characteristics and disease
recurrences
Group A Group B
Uropathogens (baseline) (%)
Gram negative 41 (53.9) 39 (50.6)
Escherichia coli 33 (80.5) 33 (84.6)
Proteus mirabilis 3 (7.3) 1 (2.6)
Klebsiella spp. 7 (17.1) 5 (12.8)
Serratta spp. 2 (4.88) 4 (10.3)
Pseudomonas aeruginosa 0 (0) 0 (0)
Enterobacter spp. 20 (48.8) 15 (38.5)
Gram positive 35 (46.1) 38 (49.4)
Enterococcus spp. 25 (71.4) 27 (71)
Staphylococcus saprophyticus 10 (28.6) 10 (26.3)
Staphylococcus epidermidis 2 (5.7) 4 (10.5)
Staphylococcus aureus 1 (2.8) 0 (0)
Streptococcus B group 6 (17.1) 4 (10.5)
Recurrences (2 months) (%) 21 (27.6) 6 (7.8)
Uropathogens (2 months) (%)
Gram negative 21 (95.4) 6 (100)
Escherichia coli 17 (81) 4 (66.7)
Proteus mirabilis 0 (0) 0 (0)
Klebsiella spp. 2 (9.5) 1 (16.7)
Serratta spp. 0 (0) 0 (0)
Pseudomonas aeruginosa 0 (0) 0 (0)
Enterobacter spp. 2 (9.5) 1 (16.7)
Gram positive 1 (4.5) 0 (0)
Enterococcus spp. 1 (100) 0 (0)
Staphylococcus saprophyticus 0 (0) 0 (0)
Staphylococcus epidermidis 0 (0) 0 (0)
Staphylococcus aureus 0 (0) 0 (0)
Streptococcus B group 0 (0) 0 (0)
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(QoL) (score range 0–12). The pain subscale includes six
items scoring from 0 to 1, one scoring from 0 to 5 and
one scoring from 0 to 10. The urinary subscale consists of
two items, both of them scored from 0 to 3. The QoL
subscale includes further two items scored from 0 to
3, and one scored from 0 to 6. The sum of all single
scores is the total score. The reason every item has a
different maximum score is because they have a different
potential. NIH-CPSI characteristics are: good reliability,
validity, and responsiveness to change. It has been used in
many large-scale trials regarding CP/CPPS as the primary
outcome variable [14]. Exclusion criteria of the study
were: positivity to Chlamydia trachomatis, Ureaplasma
urealiticum, Mycoplasma, Neisseria gonorrhoeae, herpes
simplex viruses (HSV 1/2) and human papillomavirus
(HPV); age less than 18 years; history of neurological dis-
ease, urinary stones or cancer; allergy to fluoroquinolones;
refusal to sign the informed consent; incomplete
follow-up time. Taking into account the aforementioned
criteria, 57 patients were excluded. The purpose of the
study was to evaluate the efficacy of a short lasting therapy
with a fluoroquinolone, recommended as first choice in this
disease, in association with a nutraceutical supplement. In
particular prulifloxacin, a third generation fluoroquinolone,
has demonstrated to be not-inferior to levofloxacin in
the treatment of urinary tract infections [15]. Treatment
schedule was based on oral prulifloxacin 600 mg
(Unidrox®) 1 tablet daily for 21 days and an association of
Serenoa repens 320 mg, Lactobacillus Sporogens 200 mg,Arbutin 100 mg (Lactorepens®) 1 tablet daily for 30 days.
All eligible patients signed an informed consent to
participate in the study and everyone, before the beginning
of the treatment, underwent medical history, urological
examination, Meares-Stamey test, PSA evaluation and
compiled the NIH-CPSI questionnaire (Italian version). In
order to exclude the presence of other urological disease
simulating a prostatitis, every patients had a bladder and
prostate ultrasound and compiled a voiding diary. At
2 months, 4 months and at 6 months from the start of the
therapy a follow-up examination was scheduled, and in
particular every patient underwent the same tests as at the
beginning of the treatment. Randomization was carried out
using a double-blind ratio of 1:1. Patients were divided in
two groups: Group A (76 patients) receiving antibiotic
alone and Group B (77 patients) receiving an association of
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were: clinical resolution of the disease and relief of
the symptoms. Clinical resolution was defined as being
asymptomatic for a minimum of 1 month, and clinical
failure as the persistence of symptoms together with
clinical signs (Meares-Stamey positivity) after treatment or
after the suspension of the therapy. Regarding symptoms
evaluation, we used the NIH-CPSI subscale (urinary
symptoms - score range 0–10) and we defined asymptom-
atic a patient with a score of 0. Furthermore, spontaneously
reported adverse events or those noted by the investigator
were recorded during the whole study period.
Statistical analysis was carried out with BMDP statistical
software, version 7 (Statistical Solutions, Saugus, MA) and
SPSS (Chicago, IL, version 15.00 for Windows). Statistical
significance was achieved if the p-value was <0.05. All
reported P-values are two-sided.Figure 1 NIH-CPSI questionnaire. NIH-CPSI questionnaire score at baselinThe ethical committee approval (Sapienza Rome
University - Department of Gynecological-Obstetric
Sciences and Urological Sciences - Ethical Committee)
was obtained and all treatments applied are part of routine
standard care. The study was conducted in line with
European Urology and Good Clinical Practice guidelines,
with ethical principles laid down in the latest version of
the Declaration of Helsinki. Every patient signed an
informed consent to participate in the study.
Results
Including an initial population of 210 patients and
considering the exclusion criteria, 57 patients have been
excluded. In particular, 21 patients were positive to
Chlamydia trachomatis/Ureaplasma urealiticum, 10 patients
positive to Mycoplasma and 8 positive to HPV (2 patients
Chlamydia together with Mycoplasma). Furthermore,e, 2nd, 4th and 6th month.
Table 3 NIH-CPSI questionnaire results
Group A Group B
Symptoms score (NIH-CPSI questionnaire 0–43)
(±S.D.)
Baseline 21.85 ± 5.23 22.56 ± 5.78
2 months 12.00 ± 4.34 5.23 ± 2.76
4 months 10.48 ± 4.14 4.11 ± 2.32
6 months 13.26 ± 4.88 3.67 ± 1.98
Pain score (NIH-CPSI questionnaire 0–21)
(±S.D.)
Baseline 11.65 ± 3.23 12.00 ± 2.78
2 months 6.20 ± 2.35 2.13 ± 1.90
4 months 5.82 ± 2.10 1.65 ± 1.17
6 months 8.06 ± 2.81 1.25 ± 0.99
Urinary score (NIH-CPSI questionnaire 0–10)
(±S.D.)
Baseline 4.65 ± 2.11 4.26 ± 2.28
2 months 2.35 ± 1.35 1.34 ± 0.89
4 months 2.10 ± 1.15 1.11 ± 0.89
6 months 2.65 ± 1.44 1.01 ± 0.76
Symptoms (%)
Baseline 76 (100) 77 (100)
2 months 15 (19.7) 7 (9)
4 months 18 (23.7) 7 (9)
6 months 20 (26.3) 5 (6.5)
QoL (NIH-CPSI questionnaire 0–12) (±S.D.)
Baseline 5.76 ± 2.44 5.66 ± 2.39
2 months 2.89 ± 1.68 1.85 ± 1.00
4 months 2.60 ± 1.43 1.66 ± 0.95
6 months 3.09 ± 1.74 1.40 ± 0.94
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referred an allergy to fluoroquinolones. The follow-up
time of 6 months was not reached by 10 patients. Patients’
characteristics are listed in Table 1. In our study, in total,
153 patients have been enrolled. Mean age of patients
was 36.6 ± 6.4 and median symptom time was
16.4 months (4–24). Considering uropathogens found
in the Meares-Stamey test, there was a balance between
Gram-positive and Gram-negative bacteria: 73 (47.7%)
Gram+ and 80 (52.3%) Gram – (Table 2). Biological
recurrence at 2 months (positivity of Meares-Stamey
test) in Group A was observed in 21 patients (27.6%)
and in Group B in 6 patients (7.8%). Uropathogens
found at the first follow-up were for the majority
Gram – (E. coli and Enterobacter spp.) and are listed
in Table 2. Patients with recurrence, in accordance
with antibiogram, received an alternative antibiotic
therapy without uptake of any supplement. Looking at the
NIH-CPSI questionnaire before the therapy (baseline) we
reported a score of 22.23 ± 5.55. All patients compiled the
questionnaire after 2 months, 4 months and 6 months
from the beginning of the therapy and results are as
follows: Group A 12.00 ± 4.34, Group B 5.23 ± 2.76 at
2 months; Group A 10.48 ± 4.14, Group B 4.11 ± 2.32
at 4 months; Group A 13.26 ± 4.88, Group B 3.67 ± 1.98 at
6 months (Figure 1). Data regarding the NIH-CPSI
questionnaire divided in the 3 subscales are listed in
Table 3. Furthermore, the difference between the
Groups is always statistically significant with a p value
at 2, 4 and 6 months always < 0.001. Serum median
PSA at baseline was 2.4 ± 1.8 ng/ml. PSA values after
the therapy were: Group A 1.8 ± 1.2, Group B 1.4 ± 0.9 at
2 months; Group A 1.8 ± 1.2, Group B 1.5 ± 0.9 at 4 months;
Group A 1.9 ± 1.2, Group B 1.7 ± 1.0 at 6 months (Figure 2).
After the therapy the difference between the groups isn’t
statistically significant with a p value at 2, 4 and 6 months
always > 0.05. Symptoms related to CBP have been reported
by 15 patients (19.7%) in Group A and 7 patients (9%) in
Group B at 2 months, 18 patients in Group A (23.7%) and
7 patients (9%) in Group B at 4 months, 20 patients (26.3%)
in Group A and 5 patients (6.5%) in Group B at 6 months
(Figure 3). Symptoms reported by the patients are: burning,
tenesmus, urgency, frequency, post voiding dribble and
micturition with pain. During the follow-up time all the
symptoms improved in both groups with a difference at 2,
4 and 6 months not always statistically significant; in
particular, the difference, is significant only at 4 and
6 months with a p value respectively of 0.012 and < 0.001.
All included patients received therapy properly without any
dose/tablet variation and with a compliance of 100%.
No side effects were reported with either therapy scheme
(antibiotic vs antibiotic + compound). Only patients with a
biological recurrence received an additional antibiotic
course in accordance with antibiogram.Discussion
Chronic bacterial prostatitis (CBP) type II, although its
prevalence is low, is a frustrating condition for patients
because it is characterized by a high impact on quality of
life (QoL) and also by a frequent recurrence rate [16,17].
This condition represents a challenge for urologists and,
to date, the optimal management remains controversial
and the only recommended treatment is antibiotic therapy
and surgery in those limited cases with severe complica-
tions [18,19]. Other treatments, commonly adopted, are
anti-inflammatory drugs, α-blockers, phytotherapy and
alternative therapies such as biofeedback, psychotherapy
and acupuncture [20]. Long-lasting therapy with fluori-
quinolones antibiotics is one of the best treatments in
patients with CBP because of a pharmacokinetic favourable
profile and in particular ciprofloxacin and levofloxacin
are recommended. The latter also has a favourable
action against Gram+ pathogens. Prulifloxacin, a third
generation fluoroquinolone, has been approved for the
Figure 2 PSA. Serum PSA at baseline, 2nd, 4th and 6th month.
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has demonstrated its ability to better penetrate into
prostatic tissue compared to other quinolones, thus
confirming a potential therapeutic role in the treatment of
bacterial prostatic infections [21]. Giannarini et al., com-
paring a 4-weeks course of prulifoxacin in comparison with
levofloxacin in the treatment of chronic bacterial prosta-
titis, report, at 6 months, a microbiological eradication of
72.73% and 71.11%, repectively, and a reduction in the
NIH-CPSI of 10.75 and 10.73. The authors conclude that
prulifloxacin is at last as effective and safe as levofloxacin
[15]. Serenoa repens, saw palmetto extract, the most widely
used supplement for lower urinary tracts (LUTS), and in
particular for prostatic infection and inflammation, has a
multimodal effect that is explained with a set of different
mechanisms of action: selective antagonism of the link be-
tween dihydrotestosterone and androgen receptor;inhibition of 5-alpha-reductase, involved in the transform-
ation of testosterone to its biologically active metabolite,
that stimulates cell proliferation and hypertrophy of the
prostate tissue; anti-inflammatory and anti-oedema
effect, demonstrated by reduced capillary permeability
induced by histamine; anti-estrogenic effect given by
decline in estrogen receptors, which seems to potentiate
the action of hormones in the development of BHP
[22,23]. Unlike 5-α-reductase inhibitors (5-ARI), a select-
ive competitive inhibitors of α-reductase type II that is
more specific for prostate, serenoa repens isn’t selective
and acts against both types (type I and II). Cai et al., com-
paring the usage of prulifloxacin alone with plurifloxacin in
association with serenoa repens, urtica dioica, quercitin and
curcumin in the treatment of chronic bacterial prostatitis
type II, report a statistically significant difference in QoL
and symptoms (absence of symptoms: 27% vs 89.6%) [17].
Figure 3 Symptoms. Presence of symptoms at baseline, 2nd, 4th and 6th month.
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http://www.biomedcentral.com/1471-2490/14/53Probiotics are important to reduce gastrointestinal
side-effects caused by the prolonged use of broad-band
antibiotics. Considering that pathogens found in the
prostate often derive from intestinal bacterial overgrowth,
it is important to remark the role of probiotics in
maintaining a regular intestinal bacterial flora [24].
Some authors have postulated that urethral dysbacteriosis
is one of the primary causes of CP, further contributing to
its recidivity and refractoriness [12]. In particular, when
this condition occurs, the urethral microflora infects the
prostate through prostatic reflux of urine into prostatic
ducts causing bacterial prostatitis and inflammation [25].
Overused and overprescribed antibiotics are usually
the cause of urethral dysbacteriosis while probiotics
are considered a viable potential alternative for treating
and preventing prostatitis and all urinary tract infections.Probiotics, with different mechanisms of action, have the
ability to attach to uroepithelial cells and obtain direct
antimicrobial activity [26]. The reason we suggest using
probiotics in association with a long-course antibiotic is to
rebalance intestinal bacterial flora and to avoid any urinary
tract dysbacteriosis and to prevent UTI recurrences [12].
One of the limits of many studies on chronic prostatitis is
that they focus only on infection eradication instead
of symptoms improvement. Inflammation, together with
neuromuscular spasm, is often the most important cause
of chronic prostatitis symptoms [27]. Arbutin, a glycoside
extracted from bearberry plant, is a traditional supplement
for treating UTI mainly because of its anti-inflammatory
effect due to antioxidant capability dispatched on lypopo-
lisaccharide, induced production of NO and expression of
iNOS and COX-2 [11].
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short-course, broad band antibiotic therapy (21 days of
prulifloxacin 600 mg) to eradicate pathogens in patients
with CBP and to evaluate if an association with a supple-
ment (30 days of serenoa repens 320 mg, lactobacillus
sporogens 200 mg and arbutin 100 mg) is able to prevent
recurrences and improve symptoms in those patients with
this particularly frustrating condition. To evaluate the out-
comes, patients, divided in two different groups (A and B),
have been submitted to different therapies: antibiotic or
antibiotic plus supplement. Looking at the results we can
notice, with a statistically significant difference, that patients
treated with the association of compounds obtain better
effects as demonstrated with the NIH-CPSI questionnaire.
Analysing first, second and third follow-up, patients in
Group A obtain an improvement at 2 and 4 months while
there is a decrease in results at the 6th month. Patients in
Group B obtain better results in comparison with Group A,
and furthermore the NIH-CPSI score continues to also
decrease at the 6th month follow-up. Symptoms, probably
the most invalidating condition for the patients, have been
reported by patients in Group A to improve only at 2nd
month follow-up while at 4th and 6th month there is a
turnaround. Patients in Group B continued to report
benefits till the end of follow-up time. Reported
symptoms together with the NIH-CPSI questionnaire
score are better in all patients treated with antibiotic
plus supplement, confirming more stable and long-
standing results in QoL that is always the main target of
CBP patients. Prostatic specific antigen (PSA) decreases in
both groups with a lower value in Group B probably
because of the effect of serenoa repens that acts on type I-II
5-α-reductase, inhibiting testosterone conversion to its
active metabolite. With regards to this, it is important to
remark that the prostate specific antigen does not always
increase during a prostatitis and does not seem to be
systematically correlated to prostate inflammation [28]; this
is the most important reason why it isn’t a good parameter
to show a therapy’s response. Finally we found a difference
between Group A and B in uropathogens eradication; in
particular we have a recurrence rate at 2 months of 27.6%
and 7.8%, respectively. Pathogens found during follow-up
are often different from pathogens found at baseline. We
think that the main reason is because repeated cycles of
antibiotic therapy are never able to prevent bacteria relaps-
ing [29] and this is why we can improve results by adding
compounds to antibiotic therapy alone. In particular,
results, show that association therapy obtains better results
in avoiding the majority of recurrences and prolonging the
recurrence-free time.
Limitations of the study are: small number of patients,
not randomized double-blind placebo controlled trial,
impossibility to attribute to single components of the com-
pound the action, antibiotic therapy duration scientificallydebated, and difficulty to evaluate if the results in the
patients with recurrence have been altered by different
antibiotic administered in accordance with antibiogram.
Conclusions
In summary, a broad band, short-lasting antibiotic
therapy in association with a nutritional supplement
(serenoa repens, lactobacillus sporogens and arbutin)
show better control and recurrence rates on patients
affected by chronic bacterial prostatitis, in comparison
with compared to antibiotic treatment alone.
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